Belantamab Mafodotin, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Part 1 Results of a Phase I/II Study

The authors investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly in transplant ineligible patients with newly diagnosed multiple myeloma.